Aug 2026· Discover Neuroscience· Vol 21· 0 citations· 108 references
TL;DR
Wearable neural biosensors show significant potential to enable earlier diagnosis and precision-based treatment of neurodegenerative disorders, with a focus on the disease-specific biomarkers in combination with electrophysiological and motion-based signals.
Abstract
Neurodegenerative diseases, which include Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, represent a growing worldwide health burden that can be attributed to the ageing of the population and the lack of effective modalities of early diagnosis. Conventional diagnostic methods rely on clinical assessment and neuroimaging, but they often reveal neuropathology only after it is too late, when neuronal damage has already occurred. Wearable neural biosensors are an emerging approach for continuous, non-invasive monitoring of neurophysiological, neuromuscular, and biochemical biomarkers in real-world applications. This systematic review examines of advancements in wearable biosensor design, the utilization of functional nanomaterials (graphene, CNTs, MXenes, hydrogels), signal detection modalities, and the integration of these sensors with wireless communication systems and artificial intelligence algorithms to extract clinically useful information. This review highlights applications of biosensors in the key neurodegenerative diseases, with a focus on the disease-specific biomarkers in combination with electrophysiological and motion-based signals. Challenges such as biocompatibility, long-term stability in biological fluids, data privacy, multimodal signal fusion, preclinical validation, clinical trials, regulatory systems, and ethical concerns are critically considered. The future opportunities of the multi-omics integration, personalized neuro-monitoring, and privacy-sensitive data systems are described. Overall, wearable neural biosensors show significant potential to enable earlier diagnosis and precision-based treatment of neurodegenerative disorders.
Neurodegenerative disorders (NDs), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and prion diseases, are defined by the gradual deterioration of neurons that frequently occurs prior to the onset of clinically observable symptoms. The early diagnosis of these conditions relies on analytical systems that ar...
Early diagnosis of Alzheimer's disease (AD) is critical in delaying disease progression and allows clinical management before the disease advances. Conventional diagnostic procedures, such as neuroimaging and laboratory biomarker analysis, are usually costly, invasive, and can only identify the disease in its severe st...
R. Saran, P. Jaganathan· International Conference Com...· 0 citations
The occurrence, progression, and treatment of neurological diseases are accompanied by complex humoral chemical changes, including ion imbalances, neurotransmitter disturbances, metabolic abnormalities, and abnormally elevated levels of inflammatory factors and pathological proteins. These molecular dynamics often prec...
Ting Li, Guo-Ying Pan, Yu-Heng Wang et al.· Advanced Sensor Research· 0 citations
Alzheimer's disease (AD) and Parkinson's disease (PD) are considered among the most difficult neurodegenerative diseases because they are progressive, and there are no reliable tools to make early diagnoses. Traditional diagnostic approaches, such as neuroimaging and CSF analysis, are not ideal for rapid clinical scree...
Muhammad Waqas Usmani, Abdur Rahim, Faiza Farid et al.· Talanta: The International J...· 0 citations
Acetylcholine (ACh) plays a pivotal role in cognition, learning, memory, and neuronal plasticity, and alterations in cholinergic neurotransmission are closely associated with neurodegenerative disorders, particularly Alzheimer’s disease and related dementias. Consequently, the development of analytical tools capable of...
J. P. Hervás-Pérez, Laura Muñoz-Oporto, M. Moreno-Guzmán et al.· Micromachines· 0 citations